The short version of triple agonist fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-12-08 and is reviewed periodically as new material appears.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
β-catenin binds to transcription factors such as the protein TCF4 and in combination the molecules activate the necessary genes. LF3 strongly inhibits this binding in vitro, in cell lines and reduced tumor growth in mouse models. It prevented replication and reduced their ability to migrate, all without affecting healthy cells. No cancer stem cells remained after treatment. The discovery was the product of "rational drug design", involving AlphaScreens and ELISA technologies.
==== Neurological model ==== The theoretical underpinnings of Moniz's psychosurgery were largely commensurate with the nineteenth-century ones that had informed Burckhardt's decision to excise matter from the brains of his patients. Although in his later writings, Moniz referenced both the neuron theory of Ramón y Cajal and the conditioned reflex of Ivan Pavlov, in essence he simply interpreted this new neurological research in terms of the old psychological theory of associationism. He differed significantly from Burckhardt, however in that he did not think there was any organic pathology in the brains of the mentally ill, but rather that their neural pathways were caught in fixed and destructive circuits leading to "predominant, obsessive ideas". As Moniz wrote in 1936:
Venous thrombosis is the formation of a thrombus (blood clot) in a vein. This most commonly affects a deep vein known as deep vein thrombosis (DVT), but can also affect a superficial vein known as superficial vein thrombosis (SVT).
Rood." Chevreul stressed the importance of accurate portrayal of lighting in promoting realism, but added, "It is almost always so that accurate, yet exaggerated coloring is found more pleasing than absolute fidelity to the scene." Vincent van Gogh took the advice to heart, making lavish use of complementaries to intensify one another. Van Gogh wrote, "this reciprocal heightening is what's called the law of simultaneous contrast…If the complementary colors are taken at equal value, that is to say, at the same degree of brightness and light, their juxtaposition will raise both the one and the other to an intensity so violent that human eyes will scarcely be able to bear to look at it." Chevreul was also influential in twentieth-century painting, especially that of Robert Delaunay, who was introduced to Chevreul's theories by his friend Jean Metzinger. Delaunay's style of mixing relatively large blocks of near-complementaries is today usually known as Orphism. Delaunay himself, however, preferred the name "Simultanism," a clear nod to Chevreul. Chevreul is also linked to what is sometimes called Chevreul's illusion, the bright edges that seem to exist between adjacent strips of identical colors having different intensities. See Chevreul's The Laws of Contrast of Colour for more information.
Sources: en.wikipedia.org
According to the Ebers Papyrus, a sulfur ointment was used in ancient Egypt to treat granular eyelids. There are ancient Egyptian necklaces, dated between the Ptolemaic period and the early Roman period, with beads made of sulfur, shaped like flowers and cow heads. Sulfur is one of the ingredients of niello, a dark material used to decorate metallic items. Pliny the Elder mentioned, in the first century AD, that the Romans used a type of niello inherited from the Egyptians, who, according to him, made a dark pigment to depict Anubis on silver vessels. He lists a recipe where copper and silver are mixed with sulfur and heated to produce this material. In Roman jewelry, sulfur was used as a filler in hollow gold items, especially in gold rings. This practice was widespread enough to be included by Artemidorus in the section of the Oneirocritica about gold finger-rings, where he mentions rings "that are hollow and filled with brimstone". Modern analysis has confirmed this, detecting sulfur in ancient Roman gold artifacts. In the 2nd century BC, Cato the Elder gave a recipe to protect vines against caterpillars, which contains sulfur as an ingredient, in his De Agri Cultura, an early example of its use as pest control. Pliny the Elder further discussed sulfur in his Natural History, saying that its best-known source is the island of Melos. He listed four types of sulfur: one used for medicinal purposes, one used by fullers, one used to bleach wool and one used for lamp wicks.
== Discovery == Ribosomes were first observed in the mid-1950s as dense particles or granules by Romanian-American cell biologist George Emil Palade, using an electron microscope. They were initially called Palade granules due to their granular structure. The term "ribosome" was proposed in 1958 by Howard M. Dintzis:
=== Changes that occur during the onset of gingivitis and periodontitis and its role in bleeding on probing === Following the infiltration of bacteria and its products within the sulcular epithelium, the inflammatory response triggers the release of matrix metalloproteinases which cause collagen destruction. Studies suggest that this mechanism is through the activation of Toll-Like Receptors (TLRs, such as TLR-9) which are present on epithelial cells upon binding with bacterial products (such as lipopolysaccharides, unmyelinated CpG motifs). The expression of these collagenolytic matrix metalloproteinases like MMP-13 and activated NF-κB subunit p65 (a type of transcription factor) was more commonly present in periodontitis tissue compared to gingivitis tissue, indicating that the extent of connective tissue destruction accelerates with the progression of the disease. As an effort to curb the incoming bacterial invasion, the basal cells of the sulcular epithelium, being triggered by the ongoing inflammation, proliferate in hopes to maintain an intact barrier against the bacteria and their products. Due to the ongoing inflammation, engorgement of vessels and vasodilation occurs at the underlying connective tissue of the sulcular epithelium. The concurrent destruction of the collagen will then result in the thinning or ulceration of the sulcular epithelium, making the engorged and more abundant blood capillaries more susceptible to rupture upon innocuous mechanical stimuli (such as those during toothbrushing, probing, flossing, eating).
There are more than 200 groups that we've been able to recognize that call themselves a Cherokee nation, tribe, or band," said Mike Miller, spokesman for the Cherokee Nation. "Only three are federally recognized, but the other groups run the gamut of intent. Some are basically heritage groups – people who have family with Cherokee heritage who are interested in the language and culture, and we certainly encourage that," said Miller. "But the problem is when you have groups that call themselves 'nation', or 'band', or 'tribe', because that implies governance. In 2008, the Cherokee Nation passed the Cherokee Nation Truth in Advertising for Native Art. This law states that only citizens of the three federally recognized Cherokee tribes can sell their artwork, books, or other creative works as being "Cherokee."
Eucalyptus globulus subsp. bicostata (Maiden, Blakely & Simmonds) J.B.Kirkp. (formerly Eucalyptus bicostata), commonly known as Victorian blue gum or eurabbie, has sessile flower buds arranged in groups of three; Eucalyptus globulus Labill. subsp. globulus, commonly known as Tasmanian blue gum, has flower buds arranged singly in leaf axils; Eucalyptus globulus subsp. maidenii (F.Muell.) J.B.Kirkp. (formerly Eucalyptus maidenii), commonly known as Maiden's gum has flower buds arranged in groups of seven Eucalyptus globulus subsp. pseudoglobulus (Naudin) J.B.Kirkp. (formerly Eucalyptus globulus var. pseudoglobulus), commonly known as Victorian eurabbie has pedicellate flower buds arranged in groups of three.
Sources: en.wikipedia.org
== Chemical properties == The perchlorate ion is the least redox reactive of the generalized chlorates. Perchlorate contains chlorine in its highest oxidation number (+7). A table of reduction potentials of the four chlorates shows that, contrary to expectation, perchlorate in aqueous solution is the weakest oxidant among the four.
=== 30 December === Thirty-five people were killed in an RSF drone strike on Dalang. The RSF and the SPLM-N (al-Hilu) seized the Al-Taqatu’ junction in South Kordofan, effectively cutting the main highway between Kadugli and Dalang. Both forces also seized SAF garrisons in Al-Taqatu’, Al-Balf, and Hajar Daliba.
In wound-healing in urodeles it is the quick response of anti-inflammatory macrophages which have been shown to be key to their regeneration capabilities. In one study, it was found that limbs would not regenerate in those urodeles with depleted macrophages and instead would scar with permanent loss of functionality. Knowing how regeneration occurs in animals such as these may have great implications for how wound-healing is tackled in medicine and research has been aimed at this area, as a result.
Thiobuscaline (TB), or 4-thiobuscaline (4-TB), also known as 3,5-dimethoxy-4-butylthiophenethylamine, is a psychoactive drug of the phenethylamine and scaline families related to the psychedelic drug mescaline. It is the analogue of buscaline in which the butoxy group at the 4 position has been replaced with a butylthio group. The drug is a non-hallucinogenic serotonin 5-HT2A receptor agonist with similar effects and potential uses to those of Ariadne.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.